Navigation Links
Lexicon Completes Phase 2 Study Of LX1033 In IBS-d
Date:12/3/2013

g statements," including statements relating to Lexicon's clinical development of LX1033, characterizations of the results of and projected timing of clinical trials of LX1033, and the potential therapeutic and commercial potential of LX1033.  The press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1033 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Provide First Quarter 2012 Financial Results
2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
3. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
4. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
5. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
6. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
8. Lexicon to Provide Second Quarter 2012 Financial Results
9. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
10. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
11. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
(Date:1/14/2014)... Jan. 14, 2014 The Brandeis Medical Center, led by Dr. ... a premier and affordable laser tattoo removal experience with the advanced ... is in providing high quality cosmetic services with cutting edge medical ... " Southern California has seen a dramatic increase ...
(Date:1/14/2014)... Va. , Jan. 14, 2014 Animal Emergency Critical Care, ... Leesburg, Virginia is the first in ... oxygen chamber. Dr. Susan M. Barnes , ... Dr. Barnes and husband, Dr. Cole Taylor , are avid ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:ATS Medical Announces Fourth Quarter and Full Year 2009 Results 2ATS Medical Announces Fourth Quarter and Full Year 2009 Results 3ATS Medical Announces Fourth Quarter and Full Year 2009 Results 4ATS Medical Announces Fourth Quarter and Full Year 2009 Results 5ATS Medical Announces Fourth Quarter and Full Year 2009 Results 6ATS Medical Announces Fourth Quarter and Full Year 2009 Results 7ATS Medical Announces Fourth Quarter and Full Year 2009 Results 8ATS Medical Announces Fourth Quarter and Full Year 2009 Results 9ATS Medical Announces Fourth Quarter and Full Year 2009 Results 10ATS Medical Announces Fourth Quarter and Full Year 2009 Results 11ATS Medical Announces Fourth Quarter and Full Year 2009 Results 12ATS Medical Announces Fourth Quarter and Full Year 2009 Results 13ATS Medical Announces Fourth Quarter and Full Year 2009 Results 14ATS Medical Announces Fourth Quarter and Full Year 2009 Results 15ATS Medical Announces Fourth Quarter and Full Year 2009 Results 16ATS Medical Announces Fourth Quarter and Full Year 2009 Results 17ATS Medical Announces Fourth Quarter and Full Year 2009 Results 18ATS Medical Announces Fourth Quarter and Full Year 2009 Results 19ATS Medical Announces Fourth Quarter and Full Year 2009 Results 20ATS Medical Announces Fourth Quarter and Full Year 2009 Results 21WorldHeart Reports 2009 Financial Results 2WorldHeart Reports 2009 Financial Results 3WorldHeart Reports 2009 Financial Results 4WorldHeart Reports 2009 Financial Results 5WorldHeart Reports 2009 Financial Results 6WorldHeart Reports 2009 Financial Results 7WorldHeart Reports 2009 Financial Results 8
(Date:4/17/2014)... NY (April 16, 2014) The cause of neuronal ... new study proposes that neurons may be mistaken for ... system, similar to the way autoimmune diseases like type ... body,s cells. The study was published April 16, 2014, ... new, and likely controversial, idea in Parkinson,s disease; but ...
(Date:4/17/2014)... NEW YORK April 17, 2014 EcoHealth Alliance, ... public health issues, published a comprehensive review today examining ... and Marburg virus. The review calls for improved global ... such as the recent outbreak of Ebola in West ... in the countries of Guinea and Liberia. According ...
(Date:4/17/2014)... scientists and their partners have found that their proprietary ... transmission of multiple sexually transmitted infections (STIs) in both ... virus 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded ... is effective against multiple strains of HIV, and has ... three viruses of at least eight hours prior to ...
(Date:4/17/2014)... less than 40 years away from a food shortage ... according to a top scientist at the U.S. Agency ... history, food production will be limited on a global ... said Dr. Fred Davies, senior science advisor for the ... as politically destabilizing by 2050 as energy issues are ...
(Date:4/17/2014)... whose work has transformed cancer care in Northern Ireland, ... Academy of Cancer Sciences., The Academy, which was launched ... distinguished oncologists and cancer researchers which aims to reduce ... , Professor Johnston, whose leadership has seen cancer survival ... the UK league table to near the top, has ...
Breaking Medicine News(10 mins):Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Food shortages could be most critical world issue by mid-century 2
... Society for Radiation Oncology (ASTRO), the Association of Residents ... the 2011 Educator of the Year Award. , ARRO ... recognize outstanding teachers and mentors of radiation oncology residents. ... opportunity to select one faculty member from their program ...
... UCLA,s Jonsson Comprehensive Cancer Center have developed and ... and characterizes chemical compounds that can target the ... brain tumors. Glioblastoma is one of the ... 18 months. These brain cancers consist of two ...
... , MONDAY, Oct. 10 (HealthDay News) -- In the latest ... food, Swedish scientists report that eating chocolate seems to lower ... that women who had the highest consumption of chocolate -- ... percent reduced risk of stroke. "Cocoa contains flavonoids, which ...
... mother,s womb between the father,s biological goal to produce the ... through delivery might help explain preeclampsia, an often deadly disease ... yet small enough to pass through the birth canal. In ... these conflicting goals in balance. , The findings are ...
... Legs Syndrome, you may have a higher risk of developing ... Hypertension: Journal of the American Heart Association . RLS ... intense, unpleasant leg sensations, and an irresistible urge to move ... daytime drowsiness. It affects as many as 15 percent of ...
... it is a small study and more clinical trials ... result in a reduction in brain amyloid levels in ... Online First by Archives of Neurology , one ... suggests that the accumulation of amyloid-β (Aβ) peptides in ...
Cached Medicine News:Health News:ARRO honors 39 with Educator of the Year Award 2Health News:UCLA researchers develop new way to screen for brain cancer stem cell killers 2Health News:UCLA researchers develop new way to screen for brain cancer stem cell killers 3Health News:Chocolate Could Be Sweet Defense Against Stroke 2Health News:Chocolate Could Be Sweet Defense Against Stroke 3Health News:Battle between the placenta and uterus could help explain preeclampsia 2Health News:Restless legs syndrome may raise high blood pressure risk in middle-aged women 2Health News:Small study shows association between medication and reduction in brain amyloid levels related to AD 2
Straight shafts with polished finish. Teeth: 0.12 mm. Tying platform: 5.0 mm. Wide Serrated....
Straight shafts with 0.12 mm teeth and tying platform. Serrated handle with polished finish....
Angled 45 degree shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Heavy curved shafts with 2 x 2 teeth and crisscross serrated 6 mm tying platform. Serrated handle with polished finish....
Medicine Products: